LOXL2
Lysyl • In hepatitis C and/or HIV-infected adults with advanced liver fibrosis, simtuzumab treatment (700mg by vein every 2 weeks) for 22 weeks was welltolerated.
• No significant change was seen in portal pressure gradient or liver biopsy fibrosis after 22 weeks of simtuzumab therapy, however transcriptional and protein profiling suggested up-regulation of TGF-β3 and IL-10 pathways with treatment.
• Ongoing and future studies will better define the potential role of simtuzumab in the management of liver fibrosis.
Background
Liver fibrosis is the result of chronic liver injury induced by diverse etiologies, including infection with hepatitis B and C viruses (HBV, HCV), alcohol abuse, and nonalcoholic steatohepatitis (NASH). Progressive fibrosis may result in cirrhosis and manifestations of end-stage liver disease, including portal hypertension, hepatocellular dysfunction, and hepatocellular carcinoma (1) . Effective therapeutic interventions for fibrotic liver disease remove or directly inhibit inciting fibrogenic stimuli. Unfortunately, therapeutic interventions to directly modulate fibrogenesis or enhance extracellular matrix degradation have met limited success in clinical trials (2, 3) .
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Although current treatments for chronic viral hepatitis have increased efficacy
and tolerability, not all subjects with advanced liver fibrosis experience fibrosis regression, even with curative therapy (4, 5) . Additionally, there are limited therapeutic options for NASH and other non-viral causes of fibrotic liver diseases, such as primary sclerosing cholangitis (6) . Progression of fibrosis induced by HCV or NASH may be accelerated in immunocompromised subjects, including those with HIV-infection (7, 8) .
Thus, novel approaches for treatment of advanced fibrosis are urgently needed (2, 3, 9) .
Hepatic fibrosis is characterized by increased production and deposition of fibrilforming collagens, particularly type-I collagen and matrix glycoconjugates, such as proteoglycans, fibronectins, and hyaluronic acid (10) . Matrix synthesized and deposited in the liver undergoes dynamic turnover induced by host enzymes that modify the extracellular matrix (3). This turnover is mediated in part by the lysyl oxidase family, composed of 5 enzymes that promote cross-linking of fibrillar collagen (11, 12) .
In subjects with HCV and/or NASH, expression of lysyl oxidases is confined to areas of fibrosis (12, 13) . Furthermore, LOXL2 gene and protein expression are upregulated in cancers that can arise in advanced fibrosis, including hepatocellular carcinoma (14) . In contrast to LOX expression, LOXL2 is minimally expressed in normal tissues (13) . Collectively, these data suggest lysyl oxidases contribute to fibrogenesis in a wide range of diseases and could be targeted therapeutically to modulate fibrosis progression.
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Simtuzumab is a humanized IgG4 monoclonal antibody that specifically binds and inhibits LOXL2 function in vitro and in mouse models. Allosteric inhibition of LOXL2 using simtuzumab in mouse xenograft cancer models reduced fibroblast activation and decreased growth factors and cytokine production, including transforming growth factorbeta (TGF-β) (13) . In the mouse carbon tetrachloride hepatic fibrosis model, LOXL2 was expressed in activated fibroblasts in areas of hepatic fibrosis. Furthermore, treatment
with an anti-LOXL2 antibody reduced bridging fibrosis, reduced total collagen expression, and improved survival (13) . In a pilot human study evaluating safety and tolerability in adults with liver fibrosis and chronic HCV and/or HIV infection, simtuzumab was safe and well-tolerated (15) .
Here, to ask whether simtuzumab treatment of fibrotic subjects with HCV and/or HIV infection could impact fibrosis progression, we conducted a 6-month open-label study of simtuzumab in HCV and/or HIV-infected adults with advanced liver fibrosis and explored clinical and biologic outcomes.
Methods

Design
This phase 2a, open-label, single center exploratory study assessed the safety, tolerability and potential efficacy of simtuzumab in HCV and/or HIV infected adults (NCT01707472). Study participants received 700 mg of simtuzumab (Gilead Sciences, Inc., CA) intravenously over 30 minutes every 2 weeks for 22 weeks (12 infusions).
After treatment, participants were followed every 4 weeks for an additional 12 weeks.
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This article is protected by copyright. All rights reserved. HCV infection was confirmed by positive HCV antibody and HCV RNA >2,000 IU/mL. At the time of study enrollment, no interferon-free treatments for chronic HCV infection were FDA-approved. HCV-infected subjects had a history of non-response or were unwilling or unable to receive interferon-based therapy. HIV infected subjects required an HIV viral load <40 copies/mL on stable antiretroviral therapy for over 3 months.
Study Population
The study was investigator initiated, sponsored by Gilead Sciences Inc., and was approved by the National Institute of Allergy and Infectious Diseases Institutional Review Board. All participants provided written informed consent, and the study was conducted in compliance with the Declaration of Helsinki.
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Safety Assessments
Safety was evaluated by review of adverse events and concomitant medications, assessment of clinical laboratory tests, vital signs, physical examinations, and ECG recordings. Treatment-emergent adverse events were graded by severity using
Common Terminology Criteria for Adverse Events (version 4.03).
Transjugular Liver Biopsy with Portal Pressure Measurement
Transjugular liver biopsies were performed before and after 22 weeks of treatment with simtuzumab to determine the hepatic venous pressure gradient (HVPG) and for histologic fibrosis, inflammation and steatosis staging. Peak HVPG measurements are reported. One liver biopsy core was placed in formalin for histopathologic assessment and a second core was placed in RNAlater and stored at -80°C for gene expression analysis.
Liver Histology and Immunohistochemistry
Formalin-fixed paraffin-embedded liver biopsy sections were stained with hematoxylin and eosin, Masson's trichrome, and for reticulin, and interpreted by a single liver pathologist (DEK). Fibrosis and inflammatory activity were scored with the modified histology activity index (Ishak) scoring system (16) . Steatosis was graded on a scale of 0 to 4 based on the percentage of cells with fat.
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Computer-assisted morphometry was used to quantify liver collagen content (18) and stellate cell activation was quantified by immunohistochemical staining for alphasmooth muscle actin ( were assessed at baseline and completion of therapy.
Serum LOXL2 concentrations were measured using a proprietary immunoassay (Singulex, Alameda, CA) to assess correlation with fibrosis and impact of treatment.
Auto-antibodies against simtuzumab were measured in serum at baseline and week 28 using an electrochemilumenscence assay (Biologics Development Services, Tampa, FL).
Magnetic Resonance Elastography (MRE)
In participants meeting criteria for MRE (body mass index (BMI) <35 kg/m 2 , no contraindication to MRI), MRE was performed at baseline and the end of treatment to quantify liver elasticity, a correlate of hepatic fibrosis (24), as previously described (25).
In brief, MR examination was performed on a 3.0T system (Achieva, Philips Healthcare,
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Best, Netherlands) using a 32 element surface coil. Mechanical stimulation was done using an investigational elastography package (Philips Research Laboratories, Hamburg, Germany). A mechanical transducer with a vibration frequency of 56 Hz was placed against the supine subjects' side at the lowest right rib in the right-left direction.
An operator blinded to subject, clinical parameters, and study time point, performed image processing to calculate shear wave speed in m/sec.
Efficacy Assessments
Exploratory efficacy end points included changes from baseline to end of treatment in hepatocellular inflammation and fibrosis as assessed by liver biopsy, HVPG, percent collagen, percent alpha-smooth muscle actin (SMA), and MRE shear wave speed.
Liver and Whole Blood Microarrays
Total RNA from 12 participants was extracted from paired pre-and posttreatment liver biopsies and whole blood. RNA was extracted from liver biopsies stored in RNAlater at -80°C as previously described (26). Whole blood collected and stored in PaxGene RNA tubes (Qiagen) at -80°C was extracted according to manufacturer's instructions (Qiagen, Valencia, CA).
RNA quality was determined using a 2100 Bioanalyzer (Agilent Technologies) and the Agilent RNA 6000 Pico kit. The average RNA Integrity Number (RIN) value was 7.9, with a range of 5.7 to 8.8 for liver and 4.5 to 7.7 for blood. RNA was quantitated
using a spectrophotometer (Eppendorf, Germany). RNA flow-throughs were stored at -80°C for small-and micro-RNA analysis.
cDNA for microarray analysis was synthesized using the Ovation Pico WTA system (Nugen Inc.) and used for hybridization on the Affymetrix GeneChip Human Gene 2.0 ST array. Gene expression results were analyzed in Partek Genomics Suite software (version 6.6) and normalized using the robust multi-array average method.
Results from paired liver biopsies and whole blood samples were analyzed by paired t- 
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endogenous control. GAPDH Ct values were distributed between 23 and 27. Data from 5 of 24 samples with GAPDH Ct value greater than 27 was excluded, allowing confirmatory qRT-PCR data from only 8 of 12 subjects to be reported. Expression reactions using pre-designed Taqman assays (ThermoFischer Scientific) were run on an Applied Biosystems 7500 Real-Time PCR System, as previously described (33) .
Small RNA Sequencing and Analysis
Flow-through from liver mRNA isolation was used to extract small RNAs (0 to 200 nucleotides) according to Qiagen microRNA protocol (Valencia, CA), as previously described (28).
Small RNA libraries were generated using the Illumina TruSeq Small RNA protocol following the manufacturer's instructions. Final libraries were size selected in the range of 140bp to 340bp to collect miRNA and other noncoding RNA (ncRNA).
Libraries were barcoded and sequenced on a Hiseq 2500 as 50bp single end reads.
Sequencing data were deposited at the National Center for Biotechnology Information
Sequence Read Archive, accession number SRP066098.
Sequencing reads were trimmed of adaptor sequence, reads less than 16 nucleotides or of low quality were filtered (FASTX-Toolkit). Reads were mapped and filtered as previously described (28). Paired t-test (unadjusted p-value) and false discovery rate corrected p-value (q-value) were computed using Partek Genomic Suite.
No significant species were identified with a q-value <0.05, so species with unadjusted
Accepted Article Accepted Article
p-values <0.05 were considered. Only miRNA results are reported. No technical outliers were identified and all 12 subjects were included in the analysis.
Serum Biomarkers
Paired pre-and end of treatment (week 24) cryopreserved serum samples were tested by enzyme-linked immunosorbent assays (ELISA) in multiplex for tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6, IL-2, IL-8, IL-10, IL-12p70, interferon gamma (IFNγ), and GM-CSF (MesoScale Discovery, Gaithersburg, MD). IL-7, osteopontin and tissue inhibitor of metalloproteinases-1 (TIMP1) were quantitated using single-plex assays, while TGF-β isoforms 1, 2 and 3 were quantitated using a triplex assay (MesoScale Discovery). Cleaved cytokeratin-18 levels were quantitated by ELISA (M30 Apoptosense, Peviva, West Chester, OH).
Statistical Methods
Clinical and safety variables were summarized with descriptive statistics.
Pairwise comparisons were performed using a 2-sided Wilcoxon-Mann-Whitney test. A 2 tailed p-value of <0.05 was considered statistically significant. Microarray and miRNA statistical approaches are described above, and qRT-PCR data was analyzed with nonparametric assumptions using the Wilcoxon paired-sign rank test.
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Results
Baseline Characteristics
Thirty subjects were screened and 18 enrolled prior to halting enrollment in January 2014 due to slow accrual. Twelve subjects were deemed ineligible due to: liver biopsy fibrosis (Ishak) score <3 (n=5), inadequate venous access for transjugular liver biopsy (n=2), positive illicit drug screen (n=2), Child-Pugh class >A (n=2) or cardiac arrhythmia requiring intervention (n=1). Of the 18 enrolled subjects, 6 had HCV monoinfection, 4 had HIV mono-infection with biopsy-proven NASH, and 8 had HCV/HIV coinfection. Demographic and clinical parameters are shown in Table 1 .
Most subjects were overweight (n=4, BMI 25-29.9 kg/m 
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This article is protected by copyright. All rights reserved. mmHg (range 3-15 mmHg) and was ≥10 mmHg in 4 participants (22%). Median fibrosis stage was 5 (range 3-6), median necroinflammatory grade was 8 (range [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] , and all subjects had minimal or no steatosis (Table 1) .
Safety/Adverse Events
Simtuzumab was generally safe and well tolerated and all participants completed treatment and follow-up. Treatment-emergent adverse events are summarized in Table   2 . The most common adverse events considered related to simtuzumab were fever Anti-simtuzumab antibodies were not detected in serum samples drawn at baseline or week 28.
Fibrosis and HVPG
No significant change in platelet count, albumin, liver-associated enzymes, or scores on non-invasive liver fibrosis tests was seen over the course of treatment (Table   3 ). HCV RNA levels did not change in HCV-infected subjects. CD4+ T-cell counts did not change and HIV viral load remained <400 copies/mL in HIV-infected subjects.
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In paired liver biopsies, no significant change was seen in HVPG, fibrosis, inflammation, steatosis, or percent collagen or SMA (Figure 1 ). In 4 participants with baseline HVPG ≥10, HVPG was lower by ≥20% in 2 and unchanged in 2 others at EOT.
Liver elasticity did not change in participants with baseline and end-of-treatment MRE (n=12) (Figure 1 , Table 3 ).
Gene Expression Analysis
We performed gene expression analysis on liver and blood samples to assess for Table 1) .
qRT-PCR analysis of 15 genes identified in the fibrosis pathway from liver of 8 subjects with sufficient remaining RNA revealed no significant change in expression of any individual gene (data not shown).
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Discussion
In this 6-month exploratory study we assessed the safety and tolerability of simtuzumab in HIV and/or HCV infected adults with advanced liver fibrosis, and found treatment was well-tolerated with no discontinuations due to adverse events. In contrast to preliminary findings of mild improvements in aminotransferase levels in a small dosefinding study of simtuzumab (15), however, we did not observe improvement in aminotransferases during treatment. Further, exploratory efficacy analysis identified no significant changes in liver-associated enzymes, portal pressure, liver fibrosis, liver inflammation, or liver stiffness.
While no clinical benefit was seen, our study was small and included participants with diverse viral etiologies of liver fibrosis. Absence of benefit could reflect inadequate dose or duration of treatment. Alternatively, simtuzumab inhibition of LOXL2 activity in vivo may be incomplete or compensated for by other fibrosis mediators. As is the case with many studies of antifibrotic agents, defining the optimal population, sample size, duration of treatment, and outcome measures are challenges when evaluating potential efficacy (9) .
In transcriptional and protein profiling experiments, we did not identify a clear impact of treatment using stringent statistical approaches, which may relate to the small size of liver biopsies, clinical heterogeneity of the study population, absence of sufficient RNA from all subjects for validation of target transcripts, limited sample size, or lack of efficacy of the intervention. When we employed a rank order approach to gene expression analysis to analyze the data for hypothesis generation, an increase in TGF-
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This article is protected by copyright. All rights reserved. Limitations of our study include selection bias of subjects referred and willing to undergo transjugular liver biopsy and portal pressure measurement, underreporting of alcohol use, and sampling error inherent in biopsy-based studies.
Future studies are required to explore the long-term safety and clinical efficacy of simtuzumab and potential impact of simtuzumab treatment on TGF-β3 and IL-10 pathways. Although a Phase 2 study in idiopathic pulmonary fibrosis was recently halted due to lack of efficacy, ongoing studies of simtuzumab in NASH, primary sclerosing
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